Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
07 06 2020
Historique:
received: 02 03 2020
revised: 23 03 2020
accepted: 06 05 2020
pubmed: 12 5 2020
medline: 23 6 2020
entrez: 12 5 2020
Statut: ppublish

Résumé

To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19). We enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury. The risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities.

Identifiants

pubmed: 32391877
pii: 5835730
doi: 10.1093/eurheartj/ehaa408
pmc: PMC7239100
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2070-2079

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Références

Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur Heart J. 2020 May 14;41(19):1791-1794
pubmed: 32232396
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Tex Heart Inst J. 2007;34(1):11-8
pubmed: 17420787
Circulation. 2012 Feb 14;125(6):773-81
pubmed: 22219349
Eur J Clin Invest. 2009 Jul;39(7):618-25
pubmed: 19453650
Heart Lung Circ. 2010 Feb;19(2):90-2
pubmed: 19914870
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Cardiol. 2011 Mar 17;147(3):479-82
pubmed: 21296437
Clin Infect Dis. 2008 Jul 15;47(2):182-7
pubmed: 18533841
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Clin Microbiol Infect. 2020 Jun;26(6):729-734
pubmed: 32234451
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Medicine (Baltimore). 2009 May;88(3):154-159
pubmed: 19440118
Circulation. 2003 Oct 14;108(15):1798-803
pubmed: 14504188
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Arch Intern Med. 2002 May 13;162(9):1059-64
pubmed: 11996618
Lancet. 2013 Feb 9;381(9865):496-505
pubmed: 23332146

Auteurs

Shaobo Shi (S)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Mu Qin (M)

Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China.

Yuli Cai (Y)

Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Tao Liu (T)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Bo Shen (B)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Fan Yang (F)

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Sheng Cao (S)

Department of Echocardiography, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Xu Liu (X)

Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China.

Yaozu Xiang (Y)

Shanghai East Hospital, School of Life Sciences and Technology, Advanced Institute of Translational Medicine, Tongji University, Shanghai, 200092, China.

Qinyan Zhao (Q)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

He Huang (H)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Bo Yang (B)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Congxin Huang (C)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Hubei Key Laboratory of Cardiology, Wuhan University, Wuhan, 430060, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH